ABSTRACT
Last year, the influenza vaccine did not match the circulating strains very well, and its overall protective efficacy was only 40%. All three antigens contained in the 2008-2009 vaccine are new. Surveillance data from the Southern Hemisphere during the summer of 2008 show that this vaccine is expected to match well the circulating strains in the Northern Hemisphere.
Footnotes
↵* Dr. Mossad is the site principal investigator for two studies sponsored by Hoffman-La Roche, the manufacturer of oseltamivir (Tamiflu).
- Copyright © 2008 The Cleveland Clinic Foundation. All Rights Reserved.
View Abstract
